EFFICACY OF PEMAFIBRATE ON ATHEROGENIC DYSLIPIDEMIA: RESULTS OF A POOLED ANALYSIS OF PEMAFIBRATE PHASE II/III CLINICAL TRIALS COMPARED WITH PLACEBO

被引：1
|
作者：
Ishibashi, Shun [1 ]
Arai, Hidenori [2 ]
Yokote, Koutaro [3 ,4 ]
Araki, Eiichi [5 ]
Suganami, Hideki [6 ]
Yamashita, Shizuya [7 ,8 ,9 ]
机构：
[1] Jichi Med Univ, Dept Med, Div Endocrinol & Metab, Shimotsuke, Tochigi, Japan
[2] Natl Ctr Geriatr & Gerontol, Obu, Aichi, Japan
[3] Chiba Univ, Dept Diabet Metab & Endocrinol, Grad Sch Med, Chiba, Japan
[4] Chiba Univ, Dept Clin Cell Biol & Med, Grad Sch Med, Chiba, Japan
[5] Kumamoto Univ, Fac Life Sci, Dept Metab Med, Kumamoto, Japan
[6] Kowa Co Ltd, Clin Data Sci Dept, Tokyo, Japan
[7] Rinku Gen Med Ctr, Dept Cardiol, Osaka, Japan
[8] Osaka Univ, Dept Community Med, Grad Sch Med, Osaka, Japan
[9] Osaka Univ, Dept Cardiovasc Med, Grad Sch Med, Osaka, Japan
来源：
ATHEROSCLEROSIS SUPPLEMENTS | 2018年 / 32卷
关键词：
D O I：
10.1016/j.atherosclerosissup.2018.04.075
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
C3-5.05
引用
收藏
页码：25 / 26
页数：2
相关论文
共 50 条
  • [1] A POOLED ANALYSIS OF PEMAFIBRATE PHASE II/III CLINICAL TRIALS SHOWED NO SIGNIFICANT INCREASE IN INCIDENCE OF ADVERSE EVENTS COMPARED WITH PLACEBO
    Arai, Hidenori
    Yamashita, Shizuya
    Yokote, Koutaro
    Araki, Eiichi
    Suganami, Hideki
    Ishibashi, Shun
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2018, 32 : 147 - 148
  • [2] A POOLED ANALYSIS OF PEMAFIBRATE PHASE II/III CLINICAL TRIALS INDICATED SIGNIFICANT IMPROVEMENT IN GLYCEMIC AND LIVER FUNCTION-RELATED PARAMETERS
    Yokote, Koutaro
    Yamashita, Shizuya
    Arai, Hidenori
    Araki, Eiichi
    Suganami, Hideki
    Ishibashi, Shun
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2018, 32 : 154 - 155
  • [3] Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials
    Koutaro Yokote
    Shizuya Yamashita
    Hidenori Arai
    Eiichi Araki
    Mitsunori Matsushita
    Toshiaki Nojima
    Hideki Suganami
    Shun Ishibashi
    [J]. Cardiovascular Diabetology, 20
  • [4] Phase 2 clinical trials with K-877 (pemafibrate): A promising selective PPAR-α modulator for treatment of combined dyslipidemia
    Camejo, German
    [J]. ATHEROSCLEROSIS, 2017, 261 : 163 - 164
  • [5] AKATHISIA PROFILE OF ILOPERIDONE IS SIMILAR TO PLACEBO: RESULTS FROM A POOLED ANALYSIS OF 2 PHASE III CLINICAL TRIALS
    Weiden, Peter J.
    Citrome, L.
    Hochfeld, M.
    Meng, X.
    [J]. SCHIZOPHRENIA BULLETIN, 2011, 37 : 29 - 30
  • [6] Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials
    Yokote, Koutaro
    Yamashita, Shizuya
    Arai, Hidenori
    Araki, Eiichi
    Matsushita, Mitsunori
    Nojima, Toshiaki
    Suganami, Hideki
    Ishibashi, Shun
    [J]. CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [7] PHARMACOKINETIC EVALUATION OF ORAL LACOSAMIDE IN PHASE II/III CLINICAL TRIALS: A POOLED ANALYSIS
    Cawello, W.
    Andreas, J-O
    Hebert, D.
    Eggert-Formella, A.
    [J]. EPILEPSIA, 2010, 51 : 68 - 68
  • [8] EFFICACY OF ILOPERIDONE IN EARLY-STAGE SCHIZOPHRENIA: RESULTS FROM A POOLED ANALYSIS OF 4 PHASE III CLINICAL TRIALS
    Kane, John M.
    Hochfeld, M.
    Meng, X.
    [J]. SCHIZOPHRENIA BULLETIN, 2011, 37 : 308 - 308
  • [9] Efficacy and clinical relevance of vilazodone in the treatment of major depressive disorder: a pooled analysis of phase III clinical trials
    Khan, A.
    Song, W.
    Edwards, J.
    Ruth, A.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S253 - S254
  • [10] Efficacy and clinical relevance of vilazodone in the treatment of major depressive disorder : A pooled analysis of phase III clinical trials
    Khan, A.
    Song, W.
    Ruth, A.
    Edwards, J.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 186 - 187
12345